The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk

Area of Science:

• Cardiovascular Disease Risk Assessment
• Lipid Metabolism and Cardiovascular Health
• Clinical Lipidology Guidelines

Background:

• Current National Cholesterol Education Program Adult Treatment Panel III guidelines utilize LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) targets for cardiovascular disease (CVD) risk assessment.
• Emerging evidence suggests apolipoprotein B (apo B) and the apo B/apo A-I ratio are superior predictors of CVD risk.
• A gap exists between the recognition of apolipoprotein markers and their clinical adoption due to public and professional familiarity with cholesterol metrics.

Purpose of the Study:

• To evaluate the continued relevance and efficacy of the LDL-C/HDL-C ratio in assessing cardiovascular disease risk.
• To address the practical challenges of transitioning from established cholesterol-based guidelines to novel apolipoprotein-based risk prediction.
• To provide evidence supporting the sustained utility of the LDL-C/HDL-C ratio as a standard CVD risk assessment tool.

Main Methods:

• Review of existing scientific literature and clinical guidelines concerning lipid-based cardiovascular risk assessment.
• Analysis of the comparative predictive value of cholesterol ratios versus apolipoprotein markers for CVD.
• Examination of the practical implications for patient and healthcare provider adoption of new risk assessment methodologies.

Main Results:

• The LDL-C/HDL-C ratio is presented as a valuable and standard tool for evaluating CVD risk across diverse populations.
• Despite the superior predictive power of apolipoproteins, the established familiarity and proven track record of the LDL-C/HDL-C ratio support its continued use.
• The transition to apolipoprotein-based guidelines is acknowledged as a gradual process requiring time for public and professional acceptance.

Conclusions:

• The LDL-C/HDL-C ratio remains a clinically significant and practical biomarker for cardiovascular disease risk assessment.
• Continued adherence to the LDL-C/HDL-C ratio is recommended as an efficacious strategy while apolipoprotein-based approaches gain wider recognition and integration.
• The LDL-C/HDL-C ratio serves as a reliable and accessible metric for managing lipid-lowering therapies and evaluating CVD risk in current clinical practice.